MYMD - Five Hours Of Pain Relief? Preclinical Study Shows Promising Results With This Non-Toxic CBD | Benzinga
MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) announced on Thursday the results from a preclinical study of its investigational cannabinoid Supera-CBD, a novel, synthetic, non-toxic cannabidiol (CBD) analog.
In the study, Supera-CBD targeted and quickly reduced inflammatory pain within 60 minutes, providing pain relief for up to five hours. Comparatively, traditional CBD did not affect this type of pain in the same study.
"These preclinical results illustrate the potential of Supera-CBD to alleviate acute inflammatory pain related to injuries, burns, surgery, and flare-ups from chronic inflammatory conditions such as diabetic neuropathy and shingles,” said Chris Chapman, MD, president, director and chief medical officer at MyMD.
According to a study by researchers at the academic center where the study was conducted, results indicate ...